Sustained Transdermal Delivery Method May Be Key for Alzheimer’s and Parkinson’s Patients with Dysphagia (difficulty swallowing) Englewood Cliffs, NJ, April 28, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a Joint Venture with Zylo Therapeutics.


Previous articlePharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
Next articleDelix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a Psychedelic Analog—Without Hallucinogenic Effects